Monthly Archives: June 2015

SMC approves Viekirax and Exviera for the treatment of Hepatitis C in Scotland

VIEKIRAX® (Ombitasvir / Paritaprevir / Ritonavir) + EXVIERA® (

Today the Scottish Medicines Consortium (SMC) has announced that they have approved ombitasvir/paritaprevir/ritonavir (Viekirax®) and dasabuvir (Exviera®) for use within NHS Scotland.

Both products are made by Abbvie Ltd and provide patients and clinicians with more choice in providing the new, interferon-free, Direct Acting Antivials (DAAs).  You can read the full advice on the SMC website. These new products join the four other therapies already approved for use in Scotland.

SMC approval gives the 14 Regional Health Boards in Scotland permission to use a product but it doesn’t mean that they have to use it.

The vast majority of people with bleeding disorders in Scotland who have asked for a new DAA treatment for Hepatitis C have been given access to the treatments.  If you are seeking treatment, going through treatment, or have completed treatment then we’d like to hear from you.  Please call the office or email Dan Farthing-Sykes.

European Hepatitis C Conference provides the latest information

The Irish Haemophilia Society found a very good venue.

The Irish Haemophilia Society found a very good venue.

We are very grateful to the Irish Haemophilia Society for organising a weekend conference in Malahide, near Dublin, to look at Hepatitis and Bleeding Disorders in Europe. There are almost 11,000 people in Europe with a bleeding disorder and Hepatitis C so this is one of the major issue facing the Bleeding Disorders community across the continent.

Read more